Volociximab (300 μg/eye; intravitreal injection; once weekly for 4 weeks) has well tolerance and inhibits angiogenesis in laser induced choroidal neovascularization (CNV) of cynomolgus monkey model[1]. Volociximab (10 mg/kg; i.v.; twice weekly for 3 weeks) suppresses tumor progress in rabbits VX2 model[2].
According to the laws, regulations and policies related to "patent products", the sale of this product is prohibited!
ChemicalBook prompt
The patent owner or licensee of the product has not released any relevant information for the time being.
Product Name*
CAS.No
Inquiry Amount*
Port*
Inquiry Description*
+Add Attachment (File Format: Jpg, Gif, Png, PDF,Zip,Txt,doc or xls Max Size: 3MB)
Remove